nodes	percent_of_prediction	percent_of_DWPC	metapath
Naloxone—ALB—Acitretin—psoriasis	0.0639	0.0875	CbGbCtD
Naloxone—CYP2C8—Tazarotene—psoriasis	0.0624	0.0855	CbGbCtD
Naloxone—SLCO1A2—Prednisolone—psoriasis	0.049	0.0671	CbGbCtD
Naloxone—SLCO1A2—Hydrocortisone—psoriasis	0.0465	0.0636	CbGbCtD
Naloxone—SLCO1A2—Prednisone—psoriasis	0.0463	0.0634	CbGbCtD
Naloxone—SLCO1A2—Cyclosporine—psoriasis	0.0439	0.0601	CbGbCtD
Naloxone—ALB—Mycophenolate mofetil—psoriasis	0.0299	0.0409	CbGbCtD
Naloxone—SLCO1A2—Dexamethasone—psoriasis	0.0289	0.0396	CbGbCtD
Naloxone—CYP2C8—Cholecalciferol—psoriasis	0.0267	0.0365	CbGbCtD
Naloxone—ALB—Prednisone—psoriasis	0.0239	0.0327	CbGbCtD
Naloxone—SLCO1A2—Methotrexate—psoriasis	0.0232	0.0318	CbGbCtD
Naloxone—CYP2C8—Mycophenolate mofetil—psoriasis	0.0231	0.0316	CbGbCtD
Naloxone—CYP3A4—Calcitriol—psoriasis	0.021	0.0287	CbGbCtD
Naloxone—CYP2C8—Hydrocortisone—psoriasis	0.0185	0.0254	CbGbCtD
Naloxone—CYP2C8—Cyclosporine—psoriasis	0.0175	0.024	CbGbCtD
Naloxone—CYP3A4—Methoxsalen—psoriasis	0.0163	0.0223	CbGbCtD
Naloxone—ABCB1—Mycophenolate mofetil—psoriasis	0.0156	0.0214	CbGbCtD
Naloxone—ABCB1—Betamethasone—psoriasis	0.0134	0.0184	CbGbCtD
Naloxone—ABCB1—Prednisolone—psoriasis	0.0132	0.0181	CbGbCtD
Naloxone—ABCB1—Hydrocortisone—psoriasis	0.0126	0.0172	CbGbCtD
Naloxone—ABCB1—Prednisone—psoriasis	0.0125	0.0171	CbGbCtD
Naloxone—ALB—Methotrexate—psoriasis	0.012	0.0164	CbGbCtD
Naloxone—ABCB1—Cyclosporine—psoriasis	0.0119	0.0162	CbGbCtD
Naloxone—CYP2C8—Dexamethasone—psoriasis	0.0115	0.0158	CbGbCtD
Naloxone—CYP3A4—Cholecalciferol—psoriasis	0.0108	0.0148	CbGbCtD
Naloxone—CYP3A4—Mycophenolate mofetil—psoriasis	0.00937	0.0128	CbGbCtD
Naloxone—CYP3A4—Triamcinolone—psoriasis	0.00937	0.0128	CbGbCtD
Naloxone—CYP3A4—Betamethasone—psoriasis	0.00804	0.011	CbGbCtD
Naloxone—CYP3A4—Prednisolone—psoriasis	0.00793	0.0109	CbGbCtD
Naloxone—ABCB1—Dexamethasone—psoriasis	0.00781	0.0107	CbGbCtD
Naloxone—CYP3A4—Hydrocortisone—psoriasis	0.00752	0.0103	CbGbCtD
Naloxone—CYP3A4—Prednisone—psoriasis	0.00749	0.0103	CbGbCtD
Naloxone—CYP3A4—Cyclosporine—psoriasis	0.0071	0.00973	CbGbCtD
Naloxone—ABCB1—Methotrexate—psoriasis	0.00627	0.00859	CbGbCtD
Naloxone—CYP3A4—Dexamethasone—psoriasis	0.00468	0.0064	CbGbCtD
Naloxone—Angiopathy—Hydroxyurea—psoriasis	0.00048	0.00374	CcSEcCtD
Naloxone—Body temperature increased—Methoxsalen—psoriasis	0.000477	0.00372	CcSEcCtD
Naloxone—Chills—Hydroxyurea—psoriasis	0.000475	0.0037	CcSEcCtD
Naloxone—Sweating—Mycophenolic acid—psoriasis	0.000473	0.00369	CcSEcCtD
Naloxone—Nervous system disorder—Fluocinolone Acetonide—psoriasis	0.000468	0.00365	CcSEcCtD
Naloxone—Skin disorder—Acitretin—psoriasis	0.000465	0.00362	CcSEcCtD
Naloxone—Hyperhidrosis—Acitretin—psoriasis	0.000463	0.00361	CcSEcCtD
Naloxone—Pain—Calcitriol—psoriasis	0.00046	0.00359	CcSEcCtD
Naloxone—Nausea—Beclomethasone—psoriasis	0.000458	0.00357	CcSEcCtD
Naloxone—Cardiac arrest—Prednisolone—psoriasis	0.000448	0.00349	CcSEcCtD
Naloxone—Hallucination—Mycophenolic acid—psoriasis	0.000441	0.00344	CcSEcCtD
Naloxone—Irritability—Hydrocortisone—psoriasis	0.000439	0.00343	CcSEcCtD
Naloxone—Cardiac arrest—Hydrocortisone—psoriasis	0.000438	0.00341	CcSEcCtD
Naloxone—Paraesthesia—Acitretin—psoriasis	0.00043	0.00335	CcSEcCtD
Naloxone—Abdominal pain—Calcitriol—psoriasis	0.000425	0.00332	CcSEcCtD
Naloxone—Body temperature increased—Calcitriol—psoriasis	0.000425	0.00332	CcSEcCtD
Naloxone—Pulmonary oedema—Prednisone—psoriasis	0.00042	0.00327	CcSEcCtD
Naloxone—Gastrointestinal disorder—Acitretin—psoriasis	0.000413	0.00322	CcSEcCtD
Naloxone—Cardiac arrest—Triamcinolone—psoriasis	0.000412	0.00321	CcSEcCtD
Naloxone—Gastrointestinal disorder—Fluocinolone Acetonide—psoriasis	0.000412	0.00321	CcSEcCtD
Naloxone—Hyperkinesia—Prednisone—psoriasis	0.000412	0.00321	CcSEcCtD
Naloxone—Cardiac disorder—Mycophenolic acid—psoriasis	0.000411	0.0032	CcSEcCtD
Naloxone—Pain—Acitretin—psoriasis	0.000409	0.00319	CcSEcCtD
Naloxone—Pain—Fluocinolone Acetonide—psoriasis	0.000408	0.00318	CcSEcCtD
Naloxone—Angiopathy—Mycophenolic acid—psoriasis	0.000402	0.00313	CcSEcCtD
Naloxone—Mediastinal disorder—Mycophenolic acid—psoriasis	0.000399	0.00311	CcSEcCtD
Naloxone—Convulsion—Hydroxyurea—psoriasis	0.000399	0.00311	CcSEcCtD
Naloxone—Depression—Cyclosporine—psoriasis	0.000398	0.0031	CcSEcCtD
Naloxone—Chills—Mycophenolic acid—psoriasis	0.000397	0.0031	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—psoriasis	0.000389	0.00303	CcSEcCtD
Naloxone—Depression—Mycophenolate mofetil—psoriasis	0.000388	0.00303	CcSEcCtD
Naloxone—Mental disorder—Mycophenolic acid—psoriasis	0.000388	0.00303	CcSEcCtD
Naloxone—Asthenia—Calcitriol—psoriasis	0.000386	0.00301	CcSEcCtD
Naloxone—Tension—Mycophenolic acid—psoriasis	0.000378	0.00295	CcSEcCtD
Naloxone—Abdominal pain—Acitretin—psoriasis	0.000378	0.00295	CcSEcCtD
Naloxone—Body temperature increased—Acitretin—psoriasis	0.000378	0.00295	CcSEcCtD
Naloxone—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000377	0.00294	CcSEcCtD
Naloxone—Irritability—Dexamethasone—psoriasis	0.000375	0.00293	CcSEcCtD
Naloxone—Irritability—Betamethasone—psoriasis	0.000375	0.00293	CcSEcCtD
Naloxone—Nervousness—Mycophenolic acid—psoriasis	0.000375	0.00292	CcSEcCtD
Naloxone—Cardiac arrest—Betamethasone—psoriasis	0.000374	0.00292	CcSEcCtD
Naloxone—Cardiac arrest—Dexamethasone—psoriasis	0.000374	0.00292	CcSEcCtD
Naloxone—Sweating—Mycophenolate mofetil—psoriasis	0.000373	0.00291	CcSEcCtD
Naloxone—Nervous system disorder—Hydroxyurea—psoriasis	0.000369	0.00287	CcSEcCtD
Naloxone—Diarrhoea—Calcitriol—psoriasis	0.000368	0.00287	CcSEcCtD
Naloxone—Skin disorder—Hydroxyurea—psoriasis	0.000365	0.00285	CcSEcCtD
Naloxone—Tremor—Mycophenolic acid—psoriasis	0.000361	0.00282	CcSEcCtD
Naloxone—Coma—Methotrexate—psoriasis	0.00036	0.00281	CcSEcCtD
Naloxone—Nausea—Methoxsalen—psoriasis	0.000359	0.00279	CcSEcCtD
Naloxone—Agitation—Mycophenolic acid—psoriasis	0.000354	0.00276	CcSEcCtD
Naloxone—Pulmonary oedema—Methotrexate—psoriasis	0.000351	0.00274	CcSEcCtD
Naloxone—Hallucination—Mycophenolate mofetil—psoriasis	0.000348	0.00271	CcSEcCtD
Naloxone—Asthenia—Acitretin—psoriasis	0.000343	0.00268	CcSEcCtD
Naloxone—Vomiting—Calcitriol—psoriasis	0.000342	0.00267	CcSEcCtD
Naloxone—Dyspnoea—Hydroxyurea—psoriasis	0.000335	0.00261	CcSEcCtD
Naloxone—Convulsion—Mycophenolic acid—psoriasis	0.000334	0.0026	CcSEcCtD
Naloxone—Hypertension—Mycophenolic acid—psoriasis	0.000333	0.0026	CcSEcCtD
Naloxone—Flushing—Cyclosporine—psoriasis	0.000333	0.00259	CcSEcCtD
Naloxone—Diarrhoea—Acitretin—psoriasis	0.000327	0.00255	CcSEcCtD
Naloxone—Irritability—Prednisone—psoriasis	0.000327	0.00255	CcSEcCtD
Naloxone—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000327	0.00255	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolic acid—psoriasis	0.000326	0.00254	CcSEcCtD
Naloxone—Cardiac arrest—Prednisone—psoriasis	0.000326	0.00254	CcSEcCtD
Naloxone—Angiopathy—Cyclosporine—psoriasis	0.000325	0.00253	CcSEcCtD
Naloxone—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000324	0.00253	CcSEcCtD
Naloxone—Gastrointestinal disorder—Hydroxyurea—psoriasis	0.000324	0.00253	CcSEcCtD
Naloxone—Mediastinal disorder—Cyclosporine—psoriasis	0.000323	0.00252	CcSEcCtD
Naloxone—Chills—Cyclosporine—psoriasis	0.000322	0.00251	CcSEcCtD
Naloxone—Pain—Hydroxyurea—psoriasis	0.000321	0.0025	CcSEcCtD
Naloxone—Nausea—Calcitriol—psoriasis	0.00032	0.00249	CcSEcCtD
Naloxone—Angiopathy—Mycophenolate mofetil—psoriasis	0.000317	0.00247	CcSEcCtD
Naloxone—Hallucination—Hydrocortisone—psoriasis	0.000317	0.00247	CcSEcCtD
Naloxone—Mediastinal disorder—Mycophenolate mofetil—psoriasis	0.000315	0.00246	CcSEcCtD
Naloxone—Mental disorder—Cyclosporine—psoriasis	0.000314	0.00245	CcSEcCtD
Naloxone—Chills—Mycophenolate mofetil—psoriasis	0.000314	0.00245	CcSEcCtD
Naloxone—Nervous system disorder—Mycophenolic acid—psoriasis	0.000309	0.00241	CcSEcCtD
Naloxone—Tachycardia—Mycophenolic acid—psoriasis	0.000307	0.00239	CcSEcCtD
Naloxone—Mental disorder—Mycophenolate mofetil—psoriasis	0.000306	0.00239	CcSEcCtD
Naloxone—Tension—Cyclosporine—psoriasis	0.000306	0.00239	CcSEcCtD
Naloxone—Skin disorder—Mycophenolic acid—psoriasis	0.000306	0.00238	CcSEcCtD
Naloxone—Vomiting—Acitretin—psoriasis	0.000304	0.00237	CcSEcCtD
Naloxone—Hyperhidrosis—Mycophenolic acid—psoriasis	0.000304	0.00237	CcSEcCtD
Naloxone—Vomiting—Fluocinolone Acetonide—psoriasis	0.000303	0.00237	CcSEcCtD
Naloxone—Nervousness—Cyclosporine—psoriasis	0.000303	0.00236	CcSEcCtD
Naloxone—Tension—Mycophenolate mofetil—psoriasis	0.000299	0.00233	CcSEcCtD
Naloxone—Body temperature increased—Hydroxyurea—psoriasis	0.000297	0.00232	CcSEcCtD
Naloxone—Nervousness—Mycophenolate mofetil—psoriasis	0.000296	0.0023	CcSEcCtD
Naloxone—Tremor—Cyclosporine—psoriasis	0.000292	0.00228	CcSEcCtD
Naloxone—Agitation—Cyclosporine—psoriasis	0.000287	0.00223	CcSEcCtD
Naloxone—Tremor—Mycophenolate mofetil—psoriasis	0.000285	0.00222	CcSEcCtD
Naloxone—Nausea—Acitretin—psoriasis	0.000284	0.00222	CcSEcCtD
Naloxone—Nausea—Fluocinolone Acetonide—psoriasis	0.000284	0.00221	CcSEcCtD
Naloxone—Paraesthesia—Mycophenolic acid—psoriasis	0.000283	0.0022	CcSEcCtD
Naloxone—Dyspnoea—Mycophenolic acid—psoriasis	0.000281	0.00219	CcSEcCtD
Naloxone—Agitation—Mycophenolate mofetil—psoriasis	0.00028	0.00218	CcSEcCtD
Naloxone—Mental disorder—Hydrocortisone—psoriasis	0.000279	0.00217	CcSEcCtD
Naloxone—Irritability—Methotrexate—psoriasis	0.000273	0.00213	CcSEcCtD
Naloxone—Gastrointestinal disorder—Mycophenolic acid—psoriasis	0.000272	0.00212	CcSEcCtD
Naloxone—Hallucination—Dexamethasone—psoriasis	0.000271	0.00211	CcSEcCtD
Naloxone—Hallucination—Betamethasone—psoriasis	0.000271	0.00211	CcSEcCtD
Naloxone—Convulsion—Cyclosporine—psoriasis	0.00027	0.00211	CcSEcCtD
Naloxone—Asthenia—Hydroxyurea—psoriasis	0.00027	0.0021	CcSEcCtD
Naloxone—Hypertension—Cyclosporine—psoriasis	0.000269	0.0021	CcSEcCtD
Naloxone—Pain—Mycophenolic acid—psoriasis	0.000269	0.0021	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Cyclosporine—psoriasis	0.000264	0.00206	CcSEcCtD
Naloxone—Convulsion—Mycophenolate mofetil—psoriasis	0.000264	0.00206	CcSEcCtD
Naloxone—Depression—Prednisone—psoriasis	0.000263	0.00205	CcSEcCtD
Naloxone—Hypertension—Mycophenolate mofetil—psoriasis	0.000263	0.00205	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—psoriasis	0.000257	0.00201	CcSEcCtD
Naloxone—Diarrhoea—Hydroxyurea—psoriasis	0.000257	0.002	CcSEcCtD
Naloxone—Nervous system disorder—Cyclosporine—psoriasis	0.00025	0.00195	CcSEcCtD
Naloxone—Body temperature increased—Mycophenolic acid—psoriasis	0.000249	0.00194	CcSEcCtD
Naloxone—Abdominal pain—Mycophenolic acid—psoriasis	0.000249	0.00194	CcSEcCtD
Naloxone—Skin disorder—Cyclosporine—psoriasis	0.000247	0.00193	CcSEcCtD
Naloxone—Angiopathy—Dexamethasone—psoriasis	0.000247	0.00192	CcSEcCtD
Naloxone—Angiopathy—Betamethasone—psoriasis	0.000247	0.00192	CcSEcCtD
Naloxone—Hyperhidrosis—Cyclosporine—psoriasis	0.000246	0.00192	CcSEcCtD
Naloxone—Convulsion—Prednisolone—psoriasis	0.000246	0.00192	CcSEcCtD
Naloxone—Hypertension—Prednisolone—psoriasis	0.000245	0.00191	CcSEcCtD
Naloxone—Nervous system disorder—Mycophenolate mofetil—psoriasis	0.000244	0.0019	CcSEcCtD
Naloxone—Tachycardia—Mycophenolate mofetil—psoriasis	0.000242	0.00189	CcSEcCtD
Naloxone—Skin disorder—Mycophenolate mofetil—psoriasis	0.000241	0.00188	CcSEcCtD
Naloxone—Convulsion—Hydrocortisone—psoriasis	0.00024	0.00187	CcSEcCtD
Naloxone—Hyperhidrosis—Mycophenolate mofetil—psoriasis	0.00024	0.00187	CcSEcCtD
Naloxone—Hypertension—Hydrocortisone—psoriasis	0.000239	0.00187	CcSEcCtD
Naloxone—Vomiting—Hydroxyurea—psoriasis	0.000239	0.00186	CcSEcCtD
Naloxone—Hallucination—Prednisone—psoriasis	0.000236	0.00184	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Hydrocortisone—psoriasis	0.000234	0.00183	CcSEcCtD
Naloxone—Paraesthesia—Cyclosporine—psoriasis	0.000229	0.00178	CcSEcCtD
Naloxone—Dyspnoea—Cyclosporine—psoriasis	0.000227	0.00177	CcSEcCtD
Naloxone—Convulsion—Triamcinolone—psoriasis	0.000226	0.00176	CcSEcCtD
Naloxone—Tachycardia—Prednisolone—psoriasis	0.000226	0.00176	CcSEcCtD
Naloxone—Asthenia—Mycophenolic acid—psoriasis	0.000226	0.00176	CcSEcCtD
Naloxone—Hypertension—Triamcinolone—psoriasis	0.000225	0.00176	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisolone—psoriasis	0.000224	0.00175	CcSEcCtD
Naloxone—Nausea—Hydroxyurea—psoriasis	0.000223	0.00174	CcSEcCtD
Naloxone—Paraesthesia—Mycophenolate mofetil—psoriasis	0.000223	0.00174	CcSEcCtD
Naloxone—Nervous system disorder—Hydrocortisone—psoriasis	0.000222	0.00173	CcSEcCtD
Naloxone—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000221	0.00173	CcSEcCtD
Naloxone—Tachycardia—Hydrocortisone—psoriasis	0.000221	0.00172	CcSEcCtD
Naloxone—Depression—Methotrexate—psoriasis	0.00022	0.00171	CcSEcCtD
Naloxone—Flushing—Prednisone—psoriasis	0.00022	0.00171	CcSEcCtD
Naloxone—Gastrointestinal disorder—Cyclosporine—psoriasis	0.00022	0.00171	CcSEcCtD
Naloxone—Skin disorder—Hydrocortisone—psoriasis	0.00022	0.00171	CcSEcCtD
Naloxone—Hyperhidrosis—Hydrocortisone—psoriasis	0.000219	0.00171	CcSEcCtD
Naloxone—Pain—Cyclosporine—psoriasis	0.000218	0.0017	CcSEcCtD
Naloxone—Diarrhoea—Mycophenolic acid—psoriasis	0.000215	0.00168	CcSEcCtD
Naloxone—Angiopathy—Prednisone—psoriasis	0.000215	0.00168	CcSEcCtD
Naloxone—Gastrointestinal disorder—Mycophenolate mofetil—psoriasis	0.000214	0.00167	CcSEcCtD
Naloxone—Pain—Mycophenolate mofetil—psoriasis	0.000212	0.00166	CcSEcCtD
Naloxone—Sweating—Methotrexate—psoriasis	0.000212	0.00165	CcSEcCtD
Naloxone—Paraesthesia—Prednisolone—psoriasis	0.000208	0.00162	CcSEcCtD
Naloxone—Tachycardia—Triamcinolone—psoriasis	0.000208	0.00162	CcSEcCtD
Naloxone—Mental disorder—Prednisone—psoriasis	0.000208	0.00162	CcSEcCtD
Naloxone—Hyperhidrosis—Triamcinolone—psoriasis	0.000206	0.00161	CcSEcCtD
Naloxone—Convulsion—Dexamethasone—psoriasis	0.000205	0.0016	CcSEcCtD
Naloxone—Convulsion—Betamethasone—psoriasis	0.000205	0.0016	CcSEcCtD
Naloxone—Hypertension—Betamethasone—psoriasis	0.000205	0.00159	CcSEcCtD
Naloxone—Hypertension—Dexamethasone—psoriasis	0.000205	0.00159	CcSEcCtD
Naloxone—Paraesthesia—Hydrocortisone—psoriasis	0.000203	0.00158	CcSEcCtD
Naloxone—Abdominal pain—Cyclosporine—psoriasis	0.000201	0.00157	CcSEcCtD
Naloxone—Body temperature increased—Cyclosporine—psoriasis	0.000201	0.00157	CcSEcCtD
Naloxone—Vomiting—Mycophenolic acid—psoriasis	0.0002	0.00156	CcSEcCtD
Naloxone—Pain—Prednisolone—psoriasis	0.000198	0.00154	CcSEcCtD
Naloxone—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000196	0.00153	CcSEcCtD
Naloxone—Abdominal pain—Mycophenolate mofetil—psoriasis	0.000196	0.00153	CcSEcCtD
Naloxone—Gastrointestinal disorder—Hydrocortisone—psoriasis	0.000195	0.00152	CcSEcCtD
Naloxone—Pain—Hydrocortisone—psoriasis	0.000194	0.00151	CcSEcCtD
Naloxone—Paraesthesia—Triamcinolone—psoriasis	0.000191	0.00149	CcSEcCtD
Naloxone—Dyspnoea—Triamcinolone—psoriasis	0.00019	0.00148	CcSEcCtD
Naloxone—Nervous system disorder—Dexamethasone—psoriasis	0.00019	0.00148	CcSEcCtD
Naloxone—Nervous system disorder—Betamethasone—psoriasis	0.00019	0.00148	CcSEcCtD
Naloxone—Agitation—Prednisone—psoriasis	0.00019	0.00148	CcSEcCtD
Naloxone—Tachycardia—Betamethasone—psoriasis	0.000189	0.00147	CcSEcCtD
Naloxone—Tachycardia—Dexamethasone—psoriasis	0.000189	0.00147	CcSEcCtD
Naloxone—Nausea—Mycophenolic acid—psoriasis	0.000187	0.00146	CcSEcCtD
Naloxone—Hyperhidrosis—Betamethasone—psoriasis	0.000187	0.00146	CcSEcCtD
Naloxone—Hyperhidrosis—Dexamethasone—psoriasis	0.000187	0.00146	CcSEcCtD
Naloxone—Cardiac disorder—Methotrexate—psoriasis	0.000184	0.00143	CcSEcCtD
Naloxone—Asthenia—Cyclosporine—psoriasis	0.000183	0.00142	CcSEcCtD
Naloxone—Pain—Triamcinolone—psoriasis	0.000182	0.00142	CcSEcCtD
Naloxone—Angiopathy—Methotrexate—psoriasis	0.00018	0.0014	CcSEcCtD
Naloxone—Abdominal pain—Hydrocortisone—psoriasis	0.000179	0.00139	CcSEcCtD
Naloxone—Body temperature increased—Hydrocortisone—psoriasis	0.000179	0.00139	CcSEcCtD
Naloxone—Convulsion—Prednisone—psoriasis	0.000179	0.00139	CcSEcCtD
Naloxone—Mediastinal disorder—Methotrexate—psoriasis	0.000178	0.00139	CcSEcCtD
Naloxone—Asthenia—Mycophenolate mofetil—psoriasis	0.000178	0.00139	CcSEcCtD
Naloxone—Hypertension—Prednisone—psoriasis	0.000178	0.00139	CcSEcCtD
Naloxone—Chills—Methotrexate—psoriasis	0.000178	0.00139	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	0.000174	0.00136	CcSEcCtD
Naloxone—Diarrhoea—Cyclosporine—psoriasis	0.000174	0.00136	CcSEcCtD
Naloxone—Paraesthesia—Betamethasone—psoriasis	0.000174	0.00135	CcSEcCtD
Naloxone—Paraesthesia—Dexamethasone—psoriasis	0.000174	0.00135	CcSEcCtD
Naloxone—Mental disorder—Methotrexate—psoriasis	0.000174	0.00135	CcSEcCtD
Naloxone—Diarrhoea—Mycophenolate mofetil—psoriasis	0.00017	0.00132	CcSEcCtD
Naloxone—Body temperature increased—Triamcinolone—psoriasis	0.000168	0.00131	CcSEcCtD
Naloxone—Gastrointestinal disorder—Betamethasone—psoriasis	0.000167	0.0013	CcSEcCtD
Naloxone—Gastrointestinal disorder—Dexamethasone—psoriasis	0.000167	0.0013	CcSEcCtD
Naloxone—Pain—Betamethasone—psoriasis	0.000165	0.00129	CcSEcCtD
Naloxone—Pain—Dexamethasone—psoriasis	0.000165	0.00129	CcSEcCtD
Naloxone—Nervous system disorder—Prednisone—psoriasis	0.000165	0.00129	CcSEcCtD
Naloxone—Tachycardia—Prednisone—psoriasis	0.000164	0.00128	CcSEcCtD
Naloxone—Skin disorder—Prednisone—psoriasis	0.000164	0.00127	CcSEcCtD
Naloxone—Hyperhidrosis—Prednisone—psoriasis	0.000163	0.00127	CcSEcCtD
Naloxone—Asthenia—Hydrocortisone—psoriasis	0.000162	0.00127	CcSEcCtD
Naloxone—Vomiting—Cyclosporine—psoriasis	0.000162	0.00126	CcSEcCtD
Naloxone—Vomiting—Mycophenolate mofetil—psoriasis	0.000158	0.00123	CcSEcCtD
Naloxone—Diarrhoea—Hydrocortisone—psoriasis	0.000155	0.00121	CcSEcCtD
Naloxone—Asthenia—Triamcinolone—psoriasis	0.000153	0.00119	CcSEcCtD
Naloxone—Body temperature increased—Betamethasone—psoriasis	0.000153	0.00119	CcSEcCtD
Naloxone—Abdominal pain—Betamethasone—psoriasis	0.000153	0.00119	CcSEcCtD
Naloxone—Body temperature increased—Dexamethasone—psoriasis	0.000153	0.00119	CcSEcCtD
Naloxone—Abdominal pain—Dexamethasone—psoriasis	0.000153	0.00119	CcSEcCtD
Naloxone—Nausea—Cyclosporine—psoriasis	0.000151	0.00118	CcSEcCtD
Naloxone—Paraesthesia—Prednisone—psoriasis	0.000151	0.00118	CcSEcCtD
Naloxone—Convulsion—Methotrexate—psoriasis	0.000149	0.00116	CcSEcCtD
Naloxone—Nausea—Mycophenolate mofetil—psoriasis	0.000148	0.00115	CcSEcCtD
Naloxone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	0.000146	0.00114	CcSEcCtD
Naloxone—Vomiting—Hydrocortisone—psoriasis	0.000144	0.00112	CcSEcCtD
Naloxone—Asthenia—Betamethasone—psoriasis	0.000139	0.00108	CcSEcCtD
Naloxone—Asthenia—Dexamethasone—psoriasis	0.000139	0.00108	CcSEcCtD
Naloxone—Nervous system disorder—Methotrexate—psoriasis	0.000138	0.00108	CcSEcCtD
Naloxone—Nausea—Prednisolone—psoriasis	0.000138	0.00107	CcSEcCtD
Naloxone—Skin disorder—Methotrexate—psoriasis	0.000137	0.00107	CcSEcCtD
Naloxone—Hyperhidrosis—Methotrexate—psoriasis	0.000136	0.00106	CcSEcCtD
Naloxone—Vomiting—Triamcinolone—psoriasis	0.000135	0.00106	CcSEcCtD
Naloxone—Nausea—Hydrocortisone—psoriasis	0.000134	0.00105	CcSEcCtD
Naloxone—Body temperature increased—Prednisone—psoriasis	0.000133	0.00104	CcSEcCtD
Naloxone—Abdominal pain—Prednisone—psoriasis	0.000133	0.00104	CcSEcCtD
Naloxone—Diarrhoea—Dexamethasone—psoriasis	0.000132	0.00103	CcSEcCtD
Naloxone—Diarrhoea—Betamethasone—psoriasis	0.000132	0.00103	CcSEcCtD
Naloxone—Nausea—Triamcinolone—psoriasis	0.000127	0.000986	CcSEcCtD
Naloxone—Paraesthesia—Methotrexate—psoriasis	0.000126	0.000985	CcSEcCtD
Naloxone—Dyspnoea—Methotrexate—psoriasis	0.000125	0.000978	CcSEcCtD
Naloxone—Vomiting—Dexamethasone—psoriasis	0.000123	0.000958	CcSEcCtD
Naloxone—Vomiting—Betamethasone—psoriasis	0.000123	0.000958	CcSEcCtD
Naloxone—Gastrointestinal disorder—Methotrexate—psoriasis	0.000121	0.000947	CcSEcCtD
Naloxone—Asthenia—Prednisone—psoriasis	0.000121	0.000942	CcSEcCtD
Naloxone—Pain—Methotrexate—psoriasis	0.00012	0.000938	CcSEcCtD
Naloxone—Diarrhoea—Prednisone—psoriasis	0.000115	0.000898	CcSEcCtD
Naloxone—Nausea—Dexamethasone—psoriasis	0.000115	0.000895	CcSEcCtD
Naloxone—Nausea—Betamethasone—psoriasis	0.000115	0.000895	CcSEcCtD
Naloxone—Body temperature increased—Methotrexate—psoriasis	0.000111	0.000867	CcSEcCtD
Naloxone—Abdominal pain—Methotrexate—psoriasis	0.000111	0.000867	CcSEcCtD
Naloxone—Vomiting—Prednisone—psoriasis	0.000107	0.000834	CcSEcCtD
Naloxone—Asthenia—Methotrexate—psoriasis	0.000101	0.000787	CcSEcCtD
Naloxone—Nausea—Prednisone—psoriasis	0.0001	0.00078	CcSEcCtD
Naloxone—Diarrhoea—Methotrexate—psoriasis	9.63e-05	0.00075	CcSEcCtD
Naloxone—Vomiting—Methotrexate—psoriasis	8.95e-05	0.000697	CcSEcCtD
Naloxone—Nausea—Methotrexate—psoriasis	8.36e-05	0.000651	CcSEcCtD
Naloxone—CREB1—Innate Immune System—HLA-B—psoriasis	6.35e-05	0.000449	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD8A—psoriasis	6.34e-05	0.000448	CbGpPWpGaD
Naloxone—CREB1—Toll-Like Receptors Cascades—IL6—psoriasis	6.33e-05	0.000448	CbGpPWpGaD
Naloxone—CREB1—Signaling by SCF-KIT—IL6—psoriasis	6.33e-05	0.000448	CbGpPWpGaD
Naloxone—TLR4—Immune System—CD4—psoriasis	6.32e-05	0.000447	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TAGAP—psoriasis	6.27e-05	0.000444	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-C—psoriasis	6.25e-05	0.000442	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—NFKB1—psoriasis	6.25e-05	0.000442	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—LEP—psoriasis	6.22e-05	0.00044	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—CXCL8—psoriasis	6.2e-05	0.000439	CbGpPWpGaD
Naloxone—CREB1—Immune System—TNFAIP3—psoriasis	6.17e-05	0.000437	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	6.15e-05	0.000435	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-B—psoriasis	6.09e-05	0.000431	CbGpPWpGaD
Naloxone—CREB1—Downstream signaling of activated FGFR—IL6—psoriasis	6.05e-05	0.000428	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB4—IL6—psoriasis	5.96e-05	0.000421	CbGpPWpGaD
Naloxone—OPRD1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.93e-05	0.00042	CbGpPWpGaD
Naloxone—TLR4—Innate Immune System—IL6—psoriasis	5.87e-05	0.000415	CbGpPWpGaD
Naloxone—CREB1—Myometrial Relaxation and Contraction Pathways—IL6—psoriasis	5.87e-05	0.000415	CbGpPWpGaD
Naloxone—CREB1—SIDS Susceptibility Pathways—IL6—psoriasis	5.84e-05	0.000413	CbGpPWpGaD
Naloxone—ABCB1—HIF-1-alpha transcription factor network—VEGFA—psoriasis	5.82e-05	0.000412	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	5.81e-05	0.000411	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—NFKB1—psoriasis	5.72e-05	0.000405	CbGpPWpGaD
Naloxone—ALB—Platelet degranulation—VEGFA—psoriasis	5.69e-05	0.000403	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TNF—psoriasis	5.69e-05	0.000403	CbGpPWpGaD
Naloxone—CREB1—Downstream signal transduction—IL6—psoriasis	5.69e-05	0.000403	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—VEGFA—psoriasis	5.67e-05	0.000401	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR—IL6—psoriasis	5.66e-05	0.000401	CbGpPWpGaD
Naloxone—TLR4—Immune System—JUN—psoriasis	5.66e-05	0.0004	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-A—psoriasis	5.65e-05	0.000399	CbGpPWpGaD
Naloxone—ALB—Vitamin B12 Metabolism—IL6—psoriasis	5.65e-05	0.000399	CbGpPWpGaD
Naloxone—CREB1—Signaling by ERBB2—IL6—psoriasis	5.63e-05	0.000399	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CRP—psoriasis	5.61e-05	0.000397	CbGpPWpGaD
Naloxone—CREB1—DAP12 signaling—IL6—psoriasis	5.61e-05	0.000397	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TAGAP—psoriasis	5.56e-05	0.000394	CbGpPWpGaD
Naloxone—OPRM1—G alpha (i) signalling events—CXCL8—psoriasis	5.53e-05	0.000391	CbGpPWpGaD
Naloxone—ALB—Hemostasis—ITGAL—psoriasis	5.48e-05	0.000388	CbGpPWpGaD
Naloxone—TLR4—Immune System—NFKB1—psoriasis	5.45e-05	0.000385	CbGpPWpGaD
Naloxone—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	5.42e-05	0.000384	CbGpPWpGaD
Naloxone—CREB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	5.42e-05	0.000384	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—PPARG—psoriasis	5.41e-05	0.000383	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—VDR—psoriasis	5.4e-05	0.000382	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.38e-05	0.000381	CbGpPWpGaD
Naloxone—CREB1—DAP12 interactions—IL6—psoriasis	5.27e-05	0.000373	CbGpPWpGaD
Naloxone—CREB1—Fc epsilon receptor (FCERI) signaling—IL6—psoriasis	5.27e-05	0.000373	CbGpPWpGaD
Naloxone—CREB1—Signaling by FGFR in disease—IL6—psoriasis	5.27e-05	0.000373	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR—IL6—psoriasis	5.23e-05	0.00037	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—TP53—psoriasis	5.2e-05	0.000368	CbGpPWpGaD
Naloxone—OPRK1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	5.2e-05	0.000368	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-E—psoriasis	5.19e-05	0.000367	CbGpPWpGaD
Naloxone—CREB1—Signaling by EGFR in Cancer—IL6—psoriasis	5.18e-05	0.000367	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.18e-05	0.000366	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—HLA-DRB1—psoriasis	5.16e-05	0.000365	CbGpPWpGaD
Naloxone—CREB1—Signaling by PDGF—IL6—psoriasis	5.16e-05	0.000365	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—STAT3—psoriasis	5.14e-05	0.000364	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NFKBIA—psoriasis	5.12e-05	0.000362	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	5.11e-05	0.000362	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CCL20—psoriasis	5.09e-05	0.00036	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CCL20—psoriasis	5.07e-05	0.000359	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—VEGFA—psoriasis	5.04e-05	0.000356	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—TP53—psoriasis	5.02e-05	0.000355	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—NDUFA5—psoriasis	4.96e-05	0.000351	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—ICAM1—psoriasis	4.95e-05	0.00035	CbGpPWpGaD
Naloxone—ALB—Metabolism—NDUFA5—psoriasis	4.93e-05	0.000349	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NFKBIA—psoriasis	4.91e-05	0.000348	CbGpPWpGaD
Naloxone—TLR4—Immune System—STAT3—psoriasis	4.9e-05	0.000346	CbGpPWpGaD
Naloxone—CREB1—Circadian rythm related genes—IL6—psoriasis	4.76e-05	0.000337	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TYK2—psoriasis	4.74e-05	0.000336	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—VEGFA—psoriasis	4.7e-05	0.000333	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	4.7e-05	0.000333	CbGpPWpGaD
Naloxone—CREB1—NGF signalling via TRKA from the plasma membrane—IL6—psoriasis	4.67e-05	0.00033	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.62e-05	0.000327	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	4.59e-05	0.000325	CbGpPWpGaD
Naloxone—ALB—Folate Metabolism—IL6—psoriasis	4.59e-05	0.000325	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CP—psoriasis	4.58e-05	0.000324	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—TNF—psoriasis	4.52e-05	0.00032	CbGpPWpGaD
Naloxone—OPRD1—GPCR ligand binding—CXCL8—psoriasis	4.52e-05	0.00032	CbGpPWpGaD
Naloxone—CREB1—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—psoriasis	4.51e-05	0.000319	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—APOE—psoriasis	4.49e-05	0.000318	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CCL20—psoriasis	4.45e-05	0.000315	CbGpPWpGaD
Naloxone—OPRM1—Class A/1 (Rhodopsin-like receptors)—CXCL8—psoriasis	4.4e-05	0.000311	CbGpPWpGaD
Naloxone—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	4.37e-05	0.000309	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—CARM1—psoriasis	4.36e-05	0.000308	CbGpPWpGaD
Naloxone—CREB1—Immune System—SOCS1—psoriasis	4.33e-05	0.000307	CbGpPWpGaD
Naloxone—ABCB1—Allograft Rejection—TNF—psoriasis	4.32e-05	0.000306	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—NDUFA5—psoriasis	4.32e-05	0.000305	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	4.29e-05	0.000304	CbGpPWpGaD
Naloxone—ESR1—Integrated Breast Cancer Pathway—TP53—psoriasis	4.29e-05	0.000303	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CYP2S1—psoriasis	4.21e-05	0.000298	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—TYK2—psoriasis	4.19e-05	0.000296	CbGpPWpGaD
Naloxone—ALB—Metabolism—CYP2S1—psoriasis	4.19e-05	0.000296	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CARM1—psoriasis	4.19e-05	0.000296	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.03e-05	0.000285	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	4.01e-05	0.000284	CbGpPWpGaD
Naloxone—OPRK1—GPCR ligand binding—CXCL8—psoriasis	3.96e-05	0.00028	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism of lipids and lipoproteins—PPARG—psoriasis	3.91e-05	0.000277	CbGpPWpGaD
Naloxone—ESR1—Signaling by ERBB4—IL6—psoriasis	3.9e-05	0.000276	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD8A—psoriasis	3.84e-05	0.000272	CbGpPWpGaD
Naloxone—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	3.83e-05	0.000271	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—CD4—psoriasis	3.79e-05	0.000268	CbGpPWpGaD
Naloxone—ESR1—Generic Transcription Pathway—PPARG—psoriasis	3.77e-05	0.000267	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CCL20—psoriasis	3.76e-05	0.000266	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—NFKB1—psoriasis	3.7e-05	0.000262	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-B—psoriasis	3.7e-05	0.000262	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CYP2S1—psoriasis	3.67e-05	0.00026	CbGpPWpGaD
Naloxone—ALB—Selenium Micronutrient Network—IL6—psoriasis	3.65e-05	0.000258	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—CD4—psoriasis	3.64e-05	0.000257	CbGpPWpGaD
Naloxone—CREB1—Signaling by NGF—IL6—psoriasis	3.59e-05	0.000254	CbGpPWpGaD
Naloxone—ESR1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.55e-05	0.000251	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-A—psoriasis	3.43e-05	0.000242	CbGpPWpGaD
Naloxone—TLR4—Immune System—IL6—psoriasis	3.42e-05	0.000242	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—JUN—psoriasis	3.39e-05	0.00024	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—VEGFA—psoriasis	3.36e-05	0.000237	CbGpPWpGaD
Naloxone—OPRM1—GPCR ligand binding—CXCL8—psoriasis	3.35e-05	0.000237	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CCL20—psoriasis	3.33e-05	0.000236	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—STAT3—psoriasis	3.32e-05	0.000235	CbGpPWpGaD
Naloxone—CREB1—Immune System—CRP—psoriasis	3.27e-05	0.000231	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—NFKB1—psoriasis	3.26e-05	0.000231	CbGpPWpGaD
Naloxone—CREB1—Axon guidance—IL6—psoriasis	3.25e-05	0.00023	CbGpPWpGaD
Naloxone—CREB1—Disease—HLA-A—psoriasis	3.16e-05	0.000224	CbGpPWpGaD
Naloxone—CREB1—Adaptive Immune System—NFKB1—psoriasis	3.14e-05	0.000222	CbGpPWpGaD
Naloxone—CREB1—Immune System—HLA-DRB1—psoriasis	3.13e-05	0.000221	CbGpPWpGaD
Naloxone—CREB1—Immune System—ICAM1—psoriasis	3e-05	0.000212	CbGpPWpGaD
Naloxone—CREB1—Immune System—NFKBIA—psoriasis	2.98e-05	0.000211	CbGpPWpGaD
Naloxone—CREB1—Disease—APOE—psoriasis	2.95e-05	0.000209	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—TNF—psoriasis	2.88e-05	0.000203	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	2.85e-05	0.000201	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—SOCS1—psoriasis	2.8e-05	0.000198	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—SOCS1—psoriasis	2.79e-05	0.000198	CbGpPWpGaD
Naloxone—CREB1—Disease—NOS2—psoriasis	2.75e-05	0.000195	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	2.74e-05	0.000194	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—TYK2—psoriasis	2.67e-05	0.000189	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—TYK2—psoriasis	2.66e-05	0.000188	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—NDUFA5—psoriasis	2.66e-05	0.000188	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—VDR—psoriasis	2.6e-05	0.000184	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—CAT—psoriasis	2.58e-05	0.000182	CbGpPWpGaD
Naloxone—OPRD1—GPCR downstream signaling—CXCL8—psoriasis	2.55e-05	0.000181	CbGpPWpGaD
Naloxone—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	2.53e-05	0.000179	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	2.49e-05	0.000176	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—SOCS1—psoriasis	2.45e-05	0.000173	CbGpPWpGaD
Naloxone—CREB1—Immune System—TYK2—psoriasis	2.44e-05	0.000173	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—TYK2—psoriasis	2.33e-05	0.000165	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—CXCL8—psoriasis	2.33e-05	0.000165	CbGpPWpGaD
Naloxone—CREB1—Developmental Biology—IL6—psoriasis	2.32e-05	0.000164	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—CXCL8—psoriasis	2.32e-05	0.000164	CbGpPWpGaD
Naloxone—CREB1—Immune System—IFNG—psoriasis	2.29e-05	0.000162	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CYP2S1—psoriasis	2.26e-05	0.00016	CbGpPWpGaD
Naloxone—CREB1—Disease—TYK2—psoriasis	2.25e-05	0.000159	CbGpPWpGaD
Naloxone—ALB—Hemostasis—NOS2—psoriasis	2.25e-05	0.000159	CbGpPWpGaD
Naloxone—OPRK1—GPCR downstream signaling—CXCL8—psoriasis	2.24e-05	0.000158	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.21e-05	0.000156	CbGpPWpGaD
Naloxone—CREB1—Immune System—CD4—psoriasis	2.21e-05	0.000156	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	2.2e-05	0.000155	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	2.13e-05	0.000151	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—SOCS1—psoriasis	2.07e-05	0.000146	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—APOE—psoriasis	2.07e-05	0.000146	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—LEP—psoriasis	2.07e-05	0.000146	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—LEP—psoriasis	2.06e-05	0.000146	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—APOE—psoriasis	2.06e-05	0.000146	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CARM1—psoriasis	2.06e-05	0.000146	CbGpPWpGaD
Naloxone—CREB1—Innate Immune System—IL6—psoriasis	2.05e-05	0.000145	CbGpPWpGaD
Naloxone—ALB—Metabolism—CARM1—psoriasis	2.05e-05	0.000145	CbGpPWpGaD
Naloxone—CREB1—Disease—CD4—psoriasis	2.04e-05	0.000144	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—CXCL8—psoriasis	2.03e-05	0.000144	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—APOE—psoriasis	2e-05	0.000142	CbGpPWpGaD
Naloxone—CREB1—Immune System—JUN—psoriasis	1.98e-05	0.00014	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—TYK2—psoriasis	1.97e-05	0.00014	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NFKBIA—psoriasis	1.93e-05	0.000136	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.92e-05	0.000136	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NFKBIA—psoriasis	1.92e-05	0.000136	CbGpPWpGaD
Naloxone—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.91e-05	0.000135	CbGpPWpGaD
Naloxone—CREB1—Immune System—NFKB1—psoriasis	1.9e-05	0.000135	CbGpPWpGaD
Naloxone—OPRM1—GPCR downstream signaling—CXCL8—psoriasis	1.89e-05	0.000134	CbGpPWpGaD
Naloxone—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	1.88e-05	0.000133	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—SOCS1—psoriasis	1.83e-05	0.00013	CbGpPWpGaD
Naloxone—ESR1—Gene Expression—PPARG—psoriasis	1.81e-05	0.000128	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—APOE—psoriasis	1.81e-05	0.000128	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—LEP—psoriasis	1.81e-05	0.000128	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CARM1—psoriasis	1.79e-05	0.000127	CbGpPWpGaD
Naloxone—SLCO1A2—Metabolism—PPARG—psoriasis	1.74e-05	0.000123	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—CXCL8—psoriasis	1.72e-05	0.000122	CbGpPWpGaD
Naloxone—CREB1—Immune System—STAT3—psoriasis	1.71e-05	0.000121	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NFKBIA—psoriasis	1.68e-05	0.000119	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TYK2—psoriasis	1.58e-05	0.000112	CbGpPWpGaD
Naloxone—CREB1—Disease—STAT3—psoriasis	1.58e-05	0.000112	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TYK2—psoriasis	1.57e-05	0.000111	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—LEP—psoriasis	1.53e-05	0.000108	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—APOE—psoriasis	1.53e-05	0.000108	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NFKBIA—psoriasis	1.42e-05	0.000101	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TYK2—psoriasis	1.38e-05	9.76e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—CXCL8—psoriasis	1.37e-05	9.72e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—CXCL8—psoriasis	1.37e-05	9.69e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—APOE—psoriasis	1.35e-05	9.58e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—LEP—psoriasis	1.35e-05	9.58e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling by GPCR—IL6—psoriasis	1.31e-05	9.24e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling by GPCR—IL6—psoriasis	1.3e-05	9.21e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—VEGFA—psoriasis	1.3e-05	9.21e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—JUN—psoriasis	1.28e-05	9.04e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—JUN—psoriasis	1.27e-05	9.01e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—CAT—psoriasis	1.27e-05	8.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NFKBIA—psoriasis	1.26e-05	8.93e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—CAT—psoriasis	1.26e-05	8.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—NFKB1—psoriasis	1.23e-05	8.7e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—NFKB1—psoriasis	1.23e-05	8.67e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—CXCL8—psoriasis	1.2e-05	8.5e-05	CbGpPWpGaD
Naloxone—CREB1—Immune System—IL6—psoriasis	1.19e-05	8.44e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TYK2—psoriasis	1.17e-05	8.25e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling by GPCR—IL6—psoriasis	1.14e-05	8.08e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—JUN—psoriasis	1.12e-05	7.9e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—VEGFA—psoriasis	1.12e-05	7.89e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—VEGFA—psoriasis	1.11e-05	7.87e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—STAT3—psoriasis	1.1e-05	7.82e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CARM1—psoriasis	1.1e-05	7.81e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—CAT—psoriasis	1.1e-05	7.8e-05	CbGpPWpGaD
Naloxone—CREB1—Disease—IL6—psoriasis	1.1e-05	7.8e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—STAT3—psoriasis	1.1e-05	7.79e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—NFKB1—psoriasis	1.07e-05	7.6e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TYK2—psoriasis	1.03e-05	7.31e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—CXCL8—psoriasis	1.01e-05	7.18e-05	CbGpPWpGaD
Naloxone—ALB—Hemostasis—TP53—psoriasis	9.84e-06	6.96e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—APOE—psoriasis	9.83e-06	6.96e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—APOE—psoriasis	9.78e-06	6.92e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—VEGFA—psoriasis	9.75e-06	6.9e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—STAT3—psoriasis	9.66e-06	6.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling by GPCR—IL6—psoriasis	9.65e-06	6.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—JUN—psoriasis	9.43e-06	6.67e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—NFKB1—psoriasis	9.08e-06	6.43e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—CXCL8—psoriasis	9e-06	6.37e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—APOE—psoriasis	8.57e-06	6.06e-05	CbGpPWpGaD
Naloxone—CYP2C8—Metabolism—PPARG—psoriasis	8.57e-06	6.06e-05	CbGpPWpGaD
Naloxone—ALB—Metabolism—PPARG—psoriasis	8.52e-06	6.03e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—TP53—psoriasis	8.43e-06	5.96e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—TP53—psoriasis	8.4e-06	5.95e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—JUN—psoriasis	8.37e-06	5.92e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—VEGFA—psoriasis	8.24e-06	5.83e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—STAT3—psoriasis	8.16e-06	5.77e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—NFKB1—psoriasis	8.05e-06	5.7e-05	CbGpPWpGaD
Naloxone—CREB1—Signaling Pathways—IL6—psoriasis	7.72e-06	5.46e-05	CbGpPWpGaD
Naloxone—OPRD1—Signaling Pathways—IL6—psoriasis	7.69e-06	5.44e-05	CbGpPWpGaD
Naloxone—ABCB1—Metabolism—PPARG—psoriasis	7.46e-06	5.28e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—TP53—psoriasis	7.37e-06	5.21e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—VEGFA—psoriasis	7.31e-06	5.17e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—STAT3—psoriasis	7.24e-06	5.12e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—CAT—psoriasis	6.79e-06	4.81e-05	CbGpPWpGaD
Naloxone—OPRK1—Signaling Pathways—IL6—psoriasis	6.75e-06	4.77e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—TP53—psoriasis	6.23e-06	4.41e-05	CbGpPWpGaD
Naloxone—OPRM1—Signaling Pathways—IL6—psoriasis	5.7e-06	4.03e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—TP53—psoriasis	5.52e-06	3.91e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—APOE—psoriasis	5.28e-06	3.73e-05	CbGpPWpGaD
Naloxone—ESR1—Signaling Pathways—IL6—psoriasis	5.05e-06	3.58e-05	CbGpPWpGaD
Naloxone—CYP3A4—Metabolism—PPARG—psoriasis	4.6e-06	3.25e-05	CbGpPWpGaD
